OKYO Pharma's neuropathic corneal pain study greenlit by FDA - ICYMI

OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week confirmed it is set to launch a Phase 2b/3 clinical trial for neuropathic corneal pain, following a productive Type C meeting with the US Food and Drug Administration (FDA). In a conversation with Proactive, chief executive Robert Dempsey said the regulatory meeting provided "a clear line of sight" for advancing the programme, which targets a condition he described as severely debilitating and significantly underserved. Proactive: Welcome back inside our Proac ...